Oncology

Gene therapy company 4D Molecular Therapeutics raises USD 90 Million to collaborate with AstraZeneca and Roche for moving gene therapies into clinical testing 4D Molecular Therapeutics has upraised USD 90 million in venture capital funds for progressing its vector platform and treatments, which use adeno-associated viruses for inserting genes into cells. Its lead program is 4D-110 that is delivered squarely to the eye to treat choroideremia, an inherited disorder that causes progressive vision loss and is expected to enter clinical trials next year. Arvinas slates for USD 100 Million IPO Arvinas lines up for USD100 million in its IPO. This will get its major and le...